Stock Gainers:
-
Acadia Pharmaceuticals Inc. (ACAD): The stock surged 18% in premarket trading as the company expanded drug rights to a treatment for a rare neurological disorder.
-
Roivant Sciences Ltd. (ROIV): Shares rallied nearly 10% following a Wall Street Journal report that the biotech drug maker was close to the sale of an ulcerative colitis drug to Roche Holding.
-
JPMorgan Chase & Co.: Shares rose 0.6% in premarket trading ahead of the Wall Street bank’s second-quarter results due Friday.
Stock Decliners:
-
Theseus Pharmaceuticals Inc. (THRX): Shares plummeted 64% as the drug maker announced it halted development of a cancer drug candidate.
-
Leslie’s Inc.: Shares fell 24% after the spa and pool supplies retailer announced preliminary quarterly results below expectations, dialed down its 2023 outlook, and announced a CFO transition.
-
Nokia Oyj (NOK): Shares dropped nearly 10% in premarket trading after the Finnish telecom equipment maker lowered its full-year outlook following preliminary second-quarter results. Shares of its Swedish rival Ericsson AB also fell 8.5% after meeting expectations with its results, but giving lackluster guidance.
-
Caribou Biosciences Inc. (CRBU): Shares were down 4% after the biopharma company said it had begun a $100 million share offering.